Transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) affects far more patients than most health systems realize — and the data show many are going undiagnosed and unmanaged.1-7 Recent Becker’s Healthcare and Alnylam survey research, with perspectives from more than 100 health system leaders,…
Presented by:
Presenters
Ginger Biesbrock, DSc, PA-C, MPH, FACC
SVP, National Heart and Vascular Service Line Advocate Health
Nitasha Sarswat, MD
Associate Professor of Medicine Director, Multi-Institutional Amyloid Center of Excellence Director, Infiltrative Cardiomyopathy Program Director, Amyloidosis Clinical Fellowship Director, Amyloidosis Research Fellowship Advanced Heart Failure, Mechanical Circulatory Support and Transplantation Division of Cardiology University of Chicago Medicine
Joshua S. Weber, PharmD, MBA-HCM, CSP, DPLA, 340B ACE
Senior Director/ACPO Ambulatory, Retail, & Specialty Pharmacy Services St. Luke's Healthcare
